BMY vs AZN Comparison: AI Score, Valuation, Performance and Upside
Compare Bristol-Myers Squibb and AstraZeneca by cancer drug revenue, immune-oncology pipeline, blood thinner competition, international growth, and valuation.
Use this Bristol-Myers Squibb vs AstraZeneca comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
BMY and AZN are closely matched — they split the tracked metrics evenly. BMY leads on both 1-year return (+26.53%) and forward P/E quality (9.80x vs 19.34x for AZN), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for AZN (+26.02%) than for BMY (+3.65%).
| Metric | BMY | AZN |
|---|---|---|
| AI score | 39.0 | 52.0 |
| AI rank | #1255 | #388 |
| Latest close | $60.76 | $169.73 |
| 1M return | +11.08% | -3.80% |
| 6M return | +11.49% | -4.66% |
| 1Y return | +26.53% | +22.51% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BMY | AZN |
|---|---|---|
| 1Y ago | $12.41K (+24.1%) started 2025-07-23 | $12.47K (+24.7%) started 2025-07-22 |
| 5Y ago | $12.12K (+21.2%) started 2021-07-26 | $18.17K (+81.7%) started 2021-07-22 |
| 10Y ago | $15.12K (+51.2%) started 2016-07-25 | $50.36K (+403.6%) started 2016-07-22 |
Hypothetical — past performance does not guarantee future results.
| Metric | BMY | AZN |
|---|---|---|
| Market cap | $124.04B | $263.23B |
| Trailing P/E | 17.01 | 25.52 |
| Forward P/E | 9.80 | 19.34 |
| Price/Sales | 2.07 | 4.41 |
| EV/Revenue | 3.30 | 4.79 |
| Analyst target | $62.96 | $213.89 |
| Target upside | +3.65% | +26.02% |
| Metric | BMY | AZN |
|---|---|---|
| Revenue growth | 2.60% | 12.50% |
| Earnings growth | 9.20% | 5.30% |
| EPS growth | +9.20% | +5.30% |
| FCF margin | +20.32% | +10.85% |
| Operating margin | 33.04% | N/A |
| Profit margin | 15.01% | 17.19% |
| ROIC proxy | 38.73% | 23.48% |
| Return on equity | 38.73% | 23.48% |
| Dividend yield | 4.15% | 1.87% |
| Beta | 0.23 | 0.23 |
| Debt/equity | 230.97 | 71.81 |
| Current ratio | 1.42 | 0.91 |
| Quick ratio | 1.18 | 0.70 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BMY | AZN |
|---|---|---|---|
| 1Y | Growth | +24.05% | +22.51% |
| CAGR | +24.12% | +22.53% | |
| Sharpe ratio | 0.75 | 0.71 | |
| Max drawdown | 13.42% | 21.15% | |
| Max daily drop | 5.81% | 5.70% | |
| Max wkly drop | 11.50% | 14.82% | |
| 5Y | Growth | +3.75% | +62.67% |
| CAGR | +0.74% | +10.22% | |
| Sharpe ratio | -0.03 | 0.34 | |
| Max drawdown | 47.67% | 27.87% | |
| Max daily drop | 8.51% | 8.83% | |
| Max wkly drop | 11.78% | 14.82% | |
| 10Y | Growth | +7.72% | +262.92% |
| CAGR | +0.75% | +13.76% | |
| Sharpe ratio | -0.02 | 0.46 | |
| Max drawdown | 47.67% | 27.87% | |
| Max daily drop | 15.99% | 14.91% | |
| Max wkly drop | 20.86% | 16.45% |
| Category | BMY | AZN |
|---|---|---|
| Company | BMY | AZN |
| Sector | Healthcare | N/A |
| Industry | Drug Manufacturers - General | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.